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INTRODUCTION:
Conventional oral delivery is widely used in 
pharmaceutical field to treat diseases. However, 
conventional delivery had many drawbacks and major 
drawback is non-site specificity. Some drugs are absorbed 
at specific site only. They require release at specific site or 
a release such that maximum amount of drug reaches to 
the specific site. Pharmaceutical field is now focusing 
towards such drugs which require site specificity. Gastro-
retentive delivery is one of the site specific deliveries for 
the delivery of drugs either at stomach or at intestine. It is 
obtained by retaining dosage form into stomach and drug 
is being released at controlled manner to specific site either 
in stomach, duodenum and intestine.
MERITS OF GRDDS2
 Delivery of drugs with narrow absorption window 
in the small intestine region.
 Longer residence time in the stomach could be 
advantageous for local action in the upper part of the small 
intestine, for example treatment of peptic ulcer disease.
 Improved bio-availability is expected for drugs 
that are absorbed readily upon release in the GI tract such 
as cyclosporine, ciprofloxacin, ranitidine, amoxycillin, 
captopril, etc.
 Patient compliance by making a once a day 
therapy.
 Improved therapeutic efficacy
DRUGS WHICH REQUIRE GASTRIC RETENTION3
1) Drugs acting locally in the stomach E.g.
Antacids and drugs for H. Pylori viz., Misoprostol
2) Drugs that are primarily absorbed in the
stomach E.g. Amoxycillin
3) Drugs those are poorly soluble at alkaline pH
E.g. Furosemide, Diazepam, Verapamil, etc.
4) Drugs with a narrow window of absorption E.g.
Cyclosporin, Methotrexate, Levodopa, etc.
5) Drugs which are absorbed rapidly from the
GI tract. E.g. Metonidazole, tetracycline.
6) Drugs that degrade in the colon. E.g. Ranitidine,
Metformin HCl.
LIMITATIONS OF THE TECHNIQUES OF 
GASTRORETENTION2,3
More predictable and reproducible floating properties 
should be achieved in all the extreme gastric conditions. 
1. The floating systems in patients with achlorhydria can 
be questionable in case of swellable systems, faster 
swelling properties are required and complete swelling of 
the system should be achieved well before the gastric 
emptying time. 
2. Bioadhesion in the acidic environment and high 
turnover of mucus may raise questions about the 
effectiveness of this technique. Similarly retention of high 
density systems in the antrum part under the migrating 
waves of the stomach is questionable. 
3. Not suitable for drugs that may cause gastric lesions 
e.g. Non- steroidal anti-inflammatory drugs. Drugs that are 
unstable in the strong acidic environment, these systems do 
not offer significant advantages over the conventional 
dosage forms for drugs that are absorbed throughout the 
gastrointestinal tract. 
4. The mucus on the walls of the stomach is in a state of 
constant renewal, resulting in unpredictable adherence. 
5. In all the above systems the physical integrity of the 
system is very important and primary requirement for the 
success of these systems.
ABSTRACT:
In recent years several advancements has been made in research and development of Gastro retentive drug delivery system 
to overcome the drawback of non-site specificity when drug administered orally. In order to understand various 
physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention 
time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage 
systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, 
magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes 
under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with 
gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and 
marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered.
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Table1: comparison of conventional drug delivery system and GRDDS1
CONVENTIONAL DRUG DELIVERY SYSTEM GASTRORETENTIVE DRUG DELIVERY SYSTEM
High risk of toxicity Very low risk of toxicity
Less patient compliance Improves patient compliance
Not suitable for delivery of drugs with narrow absorption 
window in small intestine region
Suitable for delivery of drugs with narrow absorption window 
in small intestine region
Not much advantageous for
-Drugs having rapid absorption through GIT
-Drugs which degrade in the colon
-Drugs acting locally in the stomach
-Drugs which are poorly at an alkaline pH
Very much advantageous for
-Drugs acting locally in the stomach
-Drugs which degrade in the colon
-Drugs having rapid absorption through GIT
No risk of dose dumping Possibility of dose dumping
DIFFERENT APPOACHES FOR GRRDS:4
OVERVIEW ON GENERAL APPROACHES TO 
GASTRIC RETENTION
Various approaches for gastro retentive drug delivery 
systems are:
A)      Floating drug delivery2
Floating Drug Delivery Systems (FDDS) have a bulk 
density lower than gastric fluids and thus remain buoyant 
in the stomach, (Fig.1), for a prolonged period of time, 
without affecting the gastric emptying rate and the drug is 
released slowly at a desired rate from the system, results in 
an increase in the gastric residence time and a better 
control of fluctuations in the plasma drug concentrations 
and after complete release of the drug, the residual system 
is emptied from the stomach.
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Figure1: Graphic of the buoyant tablet which is less 
dense than the stomach fluid and therefore remains in 
the fundus5
B)      Bio/Muco-adhesive systems2,7
Bio/muco-adhesive systems bind to the gastric epithelial 
cell surface or mucin, which extends the GRT of drug 
delivery system in the stomach. The surface epithelial 
adhesive properties of mucin have been well recognized 
and applied to the development of GRDDS based on 
bio/muco-adhesive polymers. The ability to provide 
adhesion of a drug delivery system to the gastrointestinal 
wall provides longer residence time in a particular organ 
site, thereby producing an improved effect in terms of 
local action or systemic effect. Binding of polymers to the 
mucin/epithelial surface can be divided into three 
categories:  
a. Hydration-mediated adhesion:
Certain hydrophilic polymers tend to imbibe large amount 
of water and become sticky, thereby acquiring bioadhesive 
properties.
b. Bonding-mediated adhesion:
The adhesion of polymers to a mucus/epithelial cell 
surface involves various bonding mechanisms, including 
physical-mechanical bonding and chemical bonding. 
Physical-mechanical bonds can result from the insertion of 
the adhesive material into the folds or crevices of the 
mucosa. Chemical bonds may be either covalent (primary) 
or ionic (secondary) in nature. Secondary chemical bonds 
consist of dispersive interactions (i.e., Vander Waals 
interactions) and stronger specific interactions such as 
hydrogen bonds. The hydrophilic functional groups 
responsible for forming hydrogen bonds are the hydroxyl 
and carboxylic groups.
c. Receptor-mediated adhesion:
Certain polymers bind to specific receptor sites on the cell 
surfaces, thereby enhancing the gastric retention of dosage 
forms. Various investigators have proposed different 
mucin-polymer interactions, such as:
 Wetting and swelling of the polymer to permit 
intimate contact with the biological tissue.
 Interpenetration of bioadhesive polymer chains 
and entanglement of polymer and mucin chains.
 Formation of weak chemical bonds.
 Sufficient polymer mobility to allow spreading.
 Water transport followed by mucosal dehydration 
The bioadhesive coated system when comes in contact 
with the mucus layer, various non-specific (Vander Waals, 
hydrogen bonding and/or hydrophobic interactions) or 
specific interactions occurs between the complimentary 
structures and these interactions last only until the turnover 
process of mucin and the drug delivery system should 
release its drug contents during this limited adhesion time, 
in order for a bioadhesive system to be successful.
C)      Low density systems1,2
         Low density systems(<1g/cm3) which have 
immediate buoyancy have  been developed because, the 
gas-generating systems have a lag time before floating on 
the stomach contents, during which the dosage form may 
undergo premature evacuation through the pyloric 
sphincter. These are made of low density materials, 
entrapping air or oil. Most of the low density systems are 
multiple unit systems, also called as ‘‘microballoons’’ 
because of the low-density core. The preparation of these
hollow microspheres (Fig.2), involves simple solvent 
evaporation or solvent diffusion methods. Polycarbonate, 
cellulose acetate, Eudragit S, calcium alginate, low 
methoxylated pectin and agar are commonly used as 
polymers. Drug release and buoyancy are dependent on the 
plasticizer-polymer ratio, quantity of polymer, and the 
solvent used.
Figure 2: intragastric floating system1
D) Superporous Hydrogels5,7
Conventional hydrogels, with pore size ranging between 
10 nm and 10 µm has very slow process of water 
absorption and require several hours to reach an 
equilibrium state during which premature evacuation of the 
dosage form may occur while the superporous hydrogel 
(Fig.3), having average pore size (>100 µm), swell to 
equilibrium size within a minute, due to rapid water uptake 
by capillary wetting through numerous interconnected 
open pores. Moreover they swell to a large size (swelling 
ratio 100 or more) and are intended to have sufficient 
mechanical strength to withstand pressure by gastric 
contractions. This is achieved by a co-formulation of a 
hydrophilic particulate material, Ac-Di-Sol 
(crosscarmellose sodium)
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Figure 3: On the left, Superporous Hydrogels in its dry (a) and water-swollen (b) state. On the right, schematic 
illustration of the transit of Superporous Hydrogel.16
E) High density systems1,2
These systems with a density of about 3 g/cm3 are retained 
in the rugae of the stomach and are capable of 
withstanding its peristaltic movements. A density of 2.6-
2.8 g/cm3 acts as a threshold value after which such 
systems can be retained in the lower part of the stomach. 
High density formulations include coated pellets. Coating 
is done by heavy inert material such as barium sulphate, 
zinc oxide, titanium dioxide, iron powder etc. They are 
retained in the antrum of stomach.
Figure 4: High density GRDDS16
RAFT FORMING SYSTEMS
Raft forming systems have received much attention for the 
delivery of antacids and drug delivery for gastrointestinal 
infections and disorders. A simple meaning of Raft is a flat 
structure, typically made of planks, logs, or barrels, that 
floats on water and is used for transport or as a platform 
for swimmers.8 Here also we are considering something 
that floats on gastric content of stomach. The mechanism 
involved in the raft formation includes the formation of 
viscous cohesive gel in contact with gastric fluids, wherein 
each portion of the liquid swells forming a continuous 
layer called a raft. This raft floats on gastric fluids because 
of low bulk density created by the formation of CO2. 
Usually, the system contains a gel forming agent and 
alkaline bicarbonates or carbonates responsible for the 
formation of CO2 to make the system less dense and float 
on the gastric fluids. The system contains a gel forming 
agent (e.g. alginic acid), sodium bicarbonate and acid 
neutralizer, which forms a foaming sodium alginate gel 
(raft) when in contact with gastric fluids. The raft thus 
formed floats on the gastric fluids and prevents the reflux 
of the gastric contents (i.e. gastric acid) into the esophagus 
by acting as a barrier between the stomach and esophagus. 
A patent assigned to Reckitt and Colman Products Ltd., 
describes a raft forming formulation for the treatment of 
helicobacter pylori (H. Pylori) infections in the GIT. The 
composition contained drug, alginic acid, sodium 
bicarbonate, calcium carbonate, mannitol and a sweetener. 
These ingredients were granulated, and citric acid was 
added to the granules. The formulation produces 
effervescence and aerates the raft formed, making it 
float.1,9
Figure 5: Schematic representation of raft forming 
system9
ADVANCES IN RAFT FORMING APPROCH
Alginates are established among the most versatile 
biopolymers, used in a wide range of applications.12 The 
conventional use of alginate as an excipient in drug 
products generally depends on the thickening, gel-forming, 
and stabilizing properties. Alginate-based raft-forming 
formulations have been marketed word-wide for over 30 
years under various brand names, including Gaviscon.13
They are used for the symptomatic treatment of heartburn 
and oesophagitis, and appear to act by a unique mechanism 
which differs from that of traditional antacids. In the 
presence of gastric acid, alginates precipitate, forming a 
gel. Alginate-based raft-forming formulations usually 
contain sodium or potassium bicarbonate; in the presence 
of gastric acid, the bicarbonate is converted to carbon 
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dioxide which becomes entrapped within the gel 
precipitate, converting it into foam which floats on the 
surface of the gastric contents, much like a raft on water. 
Both in vitro and in vivo studies have demonstrated that 
alginate-based rafts can entrap carbon dioxide, as well as 
antacid components contained in some formulations, thus 
providing a relatively pH-neutral barrier. Several studies 
have demonstrated that the alginate raft can preferentially 
move into the oesophagus in place, or ahead, of acidic 
gastric contents during episodes of gastro-oesophageal 
reflux; some studies further suggest that the raft can act as 
a physical barrier to reduce reflux episodes. Although 
some alginate-based formulations also contain antacid 
components which can provide significant acid 
neutralization capacity, the efficacy of these formulations 
to reduce heartburn symptoms does not appear to be totally 
dependent on the neutralization of bulk gastric contents. 
The strength of the alginate raft is dependent on several 
factors, including the amount of carbon dioxide generated 
and entrapped in the raft, the molecular properties of the 
alginate, and the presence of aluminium or calcium in the 
antacid components of the formulation. Raft formation 
occurs rapidly, often within a few seconds of dosing; 
hence alginate-containing antacids are comparable to 
traditional antacids for speed of onset of relief. Since the 
raft can be retained in the stomach for several hours, 
alginate-based raft-forming formulations can additionally 
provide longer-lasting relief than that of traditional 
antacids. Indeed, clinical studies have shown Gaviscon is 
superior to placebo, and equal to or significantly better 
than traditional antacids for relieving heartburn symptoms. 
Alginate-based, raft-forming formulations have been used 
to treat reflux symptoms in infants & children and in the 
management of heartburn and reflux during pregnancy. 
While Gaviscon is effective when used alone, it is 
compatible with, and does not interfere with the activity of 
antisecretory agents such as cimetidine. Even with the 
introduction of new antisecretory and promotility agents, 
alginate-rafting formulations will continue to have a role in 
the treatment of heartburn and reflux symptoms. Their 
unique non-systemic mechanism of action provides rapid 
and long-duration relief of heartburn and acid reflux 
symptoms.
ADVANTAGE OF RAFT FORMING SYSTEM1,2,5,9
1) They are used for the symptomatic treatment of heartburn 
and oesophagitis. It can be used in LPR. GERD, 
Laryngopharyngeal Reflux (LPR) refers to the backflow of 
stomach contents into the laryngeal and pharyngeal region. 
2) It does not interfere with the activity of promotility agent, 
antisecretory agents such as cimetidine.
3) Rapid and Long-duration of action can easily achieved by 
raft formation. It may show its action within seconds. 
4) It will not interfere with function of pyloric sphincter.
5) Better patient compliance can be achieved and it is well 
tolerated.
MARKETED PREPARATION: GAVISCON14
Gaviscon Advance is an extra strength treatment for 
heartburn and indigestion including hiatus hernia and 
gastro oesophageal reflux disease also known as GERD. It 
does not cure the condition but rather is used to control the 
unpleasant symptoms and for me it works a treat. Gaviscon 
advance is a thick creamy suspension that is available in 
two flavours. Peppermint flavor and aniseed. It is quite 
pleasant to taste but a lot of people cannot bear the taste of 
aniseed. 
MECHANISM OF ACTION OF GAVISCON:
The Gaviscon liquid is a thick suspension that on 
swallowing slides down the oesophagus into the stomach. 
It forms a barrier over the top of the stomach contents 
preventing the acid from rising into the oesophagus.
Figure 7: Scintigraph sequence showing Gaviscon Advance raft (red) above the meal (green) in the stomach. Times shown 
are post meal administration. This shows that GA remains in the stomach for 4 hours and until the meal has emptied11
WHAT DOES IT CONTAIN PER 10ml DOSE? 
1g of Sodium Alginate. (Derived from seaweed). 
200 mg of Potassium bicarbonate. 
Calcium Carbonate. 
Carbomer. 
Methyl & propyl hydroxybenzoates. (E218 & E216). 
Sodium Saccharin.
However it has quite high sodium content so it will to 
reduce their sodium intake. It is sugar and gluten free.  It is 
safe to use in pregnancy and during breast feeding. Some 
people may be allergic to some of the ingredients. 
CONCLUSION:
Controlled release gastroretentive dosage forms (CR-
GRDF) enable prolonged and continuous input of the drug 
to the upper parts of the gastrointestinal (GI) tract and 
improve the bioavailability of medications that are 
characterized by a narrow absorption window. Based on 
the literature surveyed, it may be concluded that 
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gastroretentive drug delivery offers various potential 
advantages for drug with poor bioavailability due their 
absorption is restricted to the upper gastrointestinal tract 
(GIT) and they can be delivered efficiently thereby 
maximizing their absorption and enhancing absolute 
bioavailability. And hence, it can be concluded that these 
dosage forms serve the best in the treatment of diseases 
related to the GIT , GERD and for extracting a prolonged 
action from a drug with a short half-life. Usually, the raft 
system contains a gel forming agent and alkaline 
bicarbonates or carbonates responsible for the formation of 
CO2 to make the system less dense and float on the gastric 
fluids. The system contains a gel forming agent (e.g. 
alginic acid), sodium bicarbonate and acid neutralizer, 
which forms a foaming sodium alginate gel (raft) when in 
contact with gastric fluids. The raft thus formed floats on 
the gastric fluids and prevents the reflux of the gastric 
contents (i.e. gastric acid) into the esophagus by acting as a 
barrier between the stomach and esophagus. Drug 
absorption in the gastrointestinal tract is a highly variable 
procedure and prolonging gastric retention of the dosage 
form extends the time for drug absorption. Raft forming 
system promises to be a potential approach for heartburn 
and oesophagitis.11 Although there are number of 
difficulties to be worked out to achieve prolonged this, a 
large number of companies are focusing toward 
commercializing this technique. It can be concluded that 
these dosage forms serve the best in the treatment of 
diseases related to the GIT.
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